Health Tech World explores the latest business developments in the world of health technology.
UK announces record investment to rebuild NHS
The UK has announced £29bn investment to rebuild the NHS. New investment announced at the Spending Review will enable the NHS to deliver on the government’s Plan for Change to cut waiting lists, improve patient care and modernise services.
Up to £10bn will be allocated towards technology and digital transformation, as well as training thousands more GPs and providing funding to deliver an additional 700,000 urgent NHS dentist appointments a year.
The funding boost came as the Chancellor unveiled a Spending Review to deliver Britain’s renewal, with record investment in the country’s security, health and economy.
US$10m investment for AI-powered healthcare company
AI-driven health care technology and services company Guidehealth has received US$10m investment from Emory Healthcare – Georgia’s academic health system.
The strategic investment will help to accelerate the company’s next phase of growth.
The two organisations are working together to improve primary care access and population health management for more than 400,000 individuals across Georgia.
Guidehealth’s AI-powered platform proactively identifies and manages chronic conditions like diabetes, hypertension and heart disease to enable earlier interventions and better health outcomes.
Using new technology, Emory primary care and affiliate primary care providers assess patient health needs to get ahead of chronic diseases before they develop and advance.
With the investment, Guidehealth plans to expand its platform for additional tech-healthcare services, including offering AI-powered virtual care navigation, including integrating AI that assists with self-reported blood pressure readings, as well as screenings for fall risks and depression; and moving from predictive to prescriptive analytics, which focuses more on personalised care for patients based on individual health needs.
Coalition launches to double patients treated with CAR T-cell therapy by 2030
An international coalition has launched the “CAR T Vision” with the aim of doubling the proportion of eligible patients treated with CAR T-cell therapy by 2030.
As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care.
The roadmap report provides the foundations for advocacy and action by local stakeholders to address the specific access challenges patients face in different geographies.
Building on the report, expert Working Groups will be established to translate the Vision into concrete, measurable actions, including specific recommendations and a measurement framework to track progress.
MedTech innovator unveils 65 breakthrough medtech startups in its 2025 cohort
The world’s largest accelerator for medical technology startups – MedTech Innovator (MTI) – has announced 65 companies selected for its 2025 Accelerator Cohort.
The companies represent the top four per cent of nearly 1,500 global applicants, and will participate in MTI’s flagship four-month programme.
The 2025 cohort includes early and mid-stage medical device, diagnostic, and digital health companies that will receive unparalleled mentorship, strategic guidance, and access to MTI’s ecosystem of industry-leading strategic manufacturers, investors, providers, payers, patients, and other industry stakeholders.
Companies in this year’s cohort will compete for a share of US$800,000 in non-dilutive funding, with winners selected by audience vote at major industry conferences.
Venture capital investment in women’s health startups reaching record highs
Investment in women’s health reached funding reaching new heights at US$2.6bn in 2024 despite a challenging fundraising environment, according to a new Silicon Valley Bank (SVB) report.
This surpassed 2023’s total by nearly US$1bn.
According to the report, when including funding for related diseases that affect women differently or disproportionately, total investment in the sector rose to US$10.7bn.
Leveraging SVB’s proprietary data and analysis, the 2025 Innovation in Women’s Health Report explores the current fundraising landscape, key trends, and emerging innovations across the sector.
The report also revealed that in 2024, the sector saw a 55 per cent increase in VC investment, outpacing growth in the broader healthcare industry, and that in 2023, seed and Series A deals made up 83 per cent of women’s health investments, compared to 72 per cent in the overall healthcare space.
Furthermore, the gap narrowed in 2024, with seed and Series A deals representing 70 per cent and 67 per cent, respectively, of total deals in each sector.
The report reveals that early-stage startups that are focused on filling gaps in clinical pathway guidelines for women’s health received high levels of funding, with VC investment in precision medical startups in 2024 totalling US$3.6bn, up from US$1.4bn in 2023.
To read the full report please visit: https://www.svb.com/trends-insights/reports/womens-health-report/.
New partnership to power scalable, zero-fee infrastructure for decentralised health research
Decentralised autonomous organization – AxonDAO – is partnering with SKALE, a zero gas fee blockchain network, to enhance AxonDAO’s infrastructure by enabling scalable, cost-effective, and immutable tracking of user activity and research data.
As AxonDAO expands its network of wearables, AI health models, and research tools, SKALE’s decentralised architecture will provide a vital layer of transparency and verification.
By leveraging SKALE’s high-performance blockchain, AxonDAO says it will deliver tamper-proof records of user actions and system outputs to ensure integrity without compromising privacy or cost efficiency.
AxonDAO has said that while SKALE does not directly store health data, it enables AxonDAO to validate and verify all system interactions using lightweight proofs, and that as adoption of its product suite grows, SKALE’s architecture will maintain secure and verifiable logs of every user interaction.
According to the organisation, the partnership will also support its broader roadmap, including infrastructure for clinical trials, AI-based health interventions, and global DeSci collaboration.
Discussions are underway to certify AxonDAO systems as compliant with medical-grade software standards, with SKALE providing the scalable backend needed to meet these requirements.
Hyperfine announces key executive appointments
Brain imaging health tech company Hyperfine – which has developed the first FDA-cleared AI-powered portable MRI system for the brain – has announced new key executive appointments.
The company has appointed Rob Fasciano, PhD, as chief regulatory and quality officer, and Rafael O’Halloran, PhD, as vice president of technology.
The company has stated that the leadership additions were instrumental in the development of its recent FDA clearance of Optive AI software and the company’s new Swoop scanner, and that their work will now aid the rollout of the technology globally, along with the development of future software enhancements.
Investment to combat revenue leakage in pharma patient affordability programmes
Healthcare technology company RIS Rx has confirmed it has received a significant growth investment from Summit Partners to support the company’s innovation and growth.
The company’s technology-enabled solutions help pharmaceutical manufacturers’ patient assistance programmes reach their intended recipients to support access and affordability.
Using the company’s proprietary technology and real-time analytics engine, the RIS Rx platform is designed to identify and mitigate “gross-to-net” (GTN) revenue leakage stemming from misdirected affordability programmes – estimated at US$90bn annually in the US.
RIS Rx will use the investment to accelerate product development, grow its team and enhance client services.
